LONDON — The NHS has announced that every baby born in England will receive a new genetic screening test for spinal muscular atrophy (SMA), marking one of the most significant advances in newborn healthcare in recent years.

The nationwide programme aims to identify the rare but serious inherited condition shortly after birth, allowing babies to begin treatment before symptoms develop. Health experts say early diagnosis can dramatically improve long-term outcomes, helping many children avoid severe muscle weakness and life-limiting complications.

The initiative forms part of the NHS's wider expansion of genomic medicine, with officials highlighting the growing role of genetic testing in preventing disease, improving patient care and delivering more personalised healthcare.

Medical specialists have welcomed the programme, saying newborn screening will enable faster access to specialist care while giving families earlier support and treatment options.

The rollout is expected to strengthen England's position as a global leader in genomic healthcare, with further advances in precision medicine anticipated as the NHS continues investing in cutting-edge medical technologies.